ABSTRACT
Seventh pandemic Vibrio cholerae was first identified in Cameroon in 1971, causing several sporadic disease clusters with few cases. More recent years have seen larger cholera outbreaks, but the mechanism behind these periodic outbreaks is poorly understood, and it is unclear the degree to which antibiotic resistant strains contribute to disease burden and spread. We used whole genome sequencing to characterize 14 V. cholerae isolates from the 2020 and 2021-2023 cholera epidemics in Cameroon. All these isolates belonged to the T12 lineage, and most showed the same antimicrobial resistance (AMR) pattern regardless of year. This suggests that cholera outbreaks in Cameroon are, at least in part, a continuation of the outbreaks previously reported in 2018 and as far back as 2012. This finding has important implications for cholera management since it suggests the ongoing presence of pathogenic cholera even in years with few reported cases. Similarly, the AMR results suggest the need for new treatment approaches, as resistance to many common antibiotics was found even within our limited sample set. As such, whole genome sequencing should be implemented in low-income countries such as Cameroon to improve disease surveillance and to detect and predict pathogen antibiotic resistance profiles.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this project was provided by Bill and Melinda Gates Foundation OPP1195157 and Bill and Melinda Gates Foundation INV-025321.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples used in this study were collected as part of ongoing outbreak investigations for the monitoring of cholera in Cameroon. Only leftover clinical diagnostic samples were used for sequencing. No identifying patient information was included in this study, and only bacterial isolates were sequenced. Ethical approval was granted by the University of Buea (Cameroon) Faculty of Health Sciences Institutional Review Board. Reference #: 2023/1974-02/UB/SG/IRB/FHS
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw data for all sequenced isolates is available under NCBI BioProject accession: PRJNA954566. Source data files have been provided for all figures as Supplementary Data 1-4. Laboratory protocol and bioinformatics pipeline used for analysis are publicly available at https://github.com/HopkinsIDD/minion-vc.
